loader2
Partner With Us NRI

Company details

302.75
324.65
96.55
369.55
6M Return 112.19%
1Y Return 234.17%
Mkt Cap.(Cr) 850.52
Volume 21,733
Div Yield 0.31%
OI
-
OI Chg %
-
Volume 21,733

Open Free Demat Account Online with ICICIDIRECT

SWOT

  • swot

  • technicals

  • deals

  • shareholding


EMA SMA

Delivery and volume

Financials

  • Profit and loss statement

  • Balance sheet

  • Quarterly Result

  • Ratio

Sales(Cr.)

Operating Profit(Cr.)

Profit after Tax(Cr.)

Equity

Reserves and Surplus

Debt

Sales

Operating Profit

Profit after tax

PE

Debt/Equity

P BV

INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 121.93 Cr FV: 5.00
Period MF Net Purchase / (sold) FII Net
LAST 1M 23,806.36 -39,994.59
LAST 3M 79,235.45 -52,306.79
LAST 6M 143,739.24 -201,556.99
LAST 12M 206,053.08 -176,593.86

Information

  • About Company
  • Company Info
  • Listing Info
34.5
68.71%
44.9525
9.53%
7.88%
Description
  • Promoted by J S Kochhar in 1978, Jagsonpal Pharmaceuticals is engaged in the manufacture and marketing bulk drugs and pharmaceuticals at its plant at Faridabad in Haryana. The company has adopted the strategy of clubbing all its products in seven groups for effective marketing and reducing costs. Simultaneously it has geared up to set up an ultra modern multi-purpose basic drugs and formulation plant through its subsidiary, Jagsonpal Exports India Pvt Ltd. The company has a strategic alliance with Fidia Spa, Italy; and B Spofola, Czechoslovakia; to manufacture sophisticated drugs in India. It has tied up with another Israel-based company, Makhteshim Chemical Works, for acquiring the marketing rights of an anti-oxidant product. In 1994, the company has also promoted Aresco Financial Services, a new financial company. The Company`s R&D activities have resulted in manufacturing process upgradation, improving packaging, and cost containment. It`s R&D activities are geared towards development of new product technologies which can be commercialised in future. It has tied up with Lycored Natural Products Industries (LNP) of Israel, to launch a completely natural Lycopene bioactive product, Lycored, in India and SouthEast Asia. In the fiscal 2001, the company`s sales grew by 15% to Rs 136.52 crore and the profit at the net level was up 8% to Rs 10.15 crore. This was achieved against heavy odds, such as, sluggish market trends, lower growth rate of the industry and severe competition from drug majors. However the company has introduced various measures to counter the above factors so as to achieve continued growth and opportunity.

Read More

Registered Address

T-210 J, Shahpur Jat, New Delhi, New Delhi, 110049

Tel : 91-011-46181100/46109900
Email : nandita.singh:jagsonpal.com
Website : http://www.jagsonpal.com

Registrar

MCS Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 507789
NSE Code : JAGSNPHARM
Book Closure Date (Month) : Sep
BSE Group : B
ISIN : INE048B01027

ICICIdirect Jagsonpal Pharmaceuticals Ltd FAQ

You can buy Jagsonpal Pharmaceuticals Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Jagsonpal Pharmaceuticals Ltd Share.
Company share prices and volatile and keep changing according to the market conditions. As of May 20, 2022 04:01 PM the closing price of Jagsonpal Pharmaceuticals Ltd was ₹ 324.65.
Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of May 20, 2022 04:01 PM, the market cap of Jagsonpal Pharmaceuticals Ltd stood at ₹ 850.52.
The latest PE ratio of Jagsonpal Pharmaceuticals Ltd as of May 20, 2022 04:01 PM is 34.5
The latest PB ratio of Jagsonpal Pharmaceuticals Ltd as of May 20, 2022 04:01 PM is 0.14
The 52-week high of Jagsonpal Pharmaceuticals Ltd is ₹ 369.55 while the 52-week low is ₹ 96.55 .

Thank you for subscribing to Equity/ Equity Research/MF/FnO Newsletter. You will hear from us shortly.

for your vote

CLOSE